

Publisher: Bentham Science Publishers
E-ISSN: 1873-4316|12|11|1743-1751
ISSN: 1389-2010
Source: Current Pharmaceutical Biotechnology, Vol.12, Iss.11, 2011-11, pp. : 1743-1751
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The endoperoxide sesquiterpene lactone artemisinin which is isolated from the plant Artemisia annua, and its semi-synthetic derivatives, are potent, novel, antimalarial drugs. They are effective against multidrug-resistant Plasmodium strains and have become essential components of the so-called Artemisinin-based Combination Therapy, that is recommended by the World Health Organization as the treatment of choice for malaria tropica. Moreover, artemisinin and its derivatives show additional anti-parasite, antitumor, and anti-viral properties. The plants, however, are very poor resources for the drug, as the content of artemisinin is low (from 0,1 to 1,5 % of dried leaves) and dependent on seasonal and somatic variations as well as the infestation of bacteria, fungi and insects. A chemical synthesis of the compound is complex and uneconomic. Therefore, artemisinin is in short supply and remains unaffordable for most people in malariaendemic countries. Thus, many researchers have focused on enhancing the production of artemisinin, first, through traditional breeding and in in vitro plant tissue cultures and, then, by heterologous expression systems (a semi-synthetic approach) with the use of genetically-modified or transgenic microbes. In this review, we summarize the progress made in the production of artemisinin by the biotechnological approach.
Related content


Recent Advances in Artemisinin Production Through Heterologous Expression
Current Medicinal Chemistry, Vol. 15, Iss. 27, 2008-11 ,pp. :






Improvement of Generic Sevoflurane by a New Production Process
Letters in Drug Design & Discovery, Vol. 11, Iss. 4, 2014-05 ,pp. :